Proteasome-activating peptide 1 是一种肽，其作用是提升胰凝乳蛋白酶样蛋白酶体（proteasome）的催化活性，有效增强体外及细胞培养环境下的蛋白质降解效率。此外，该肽能阻止肌萎缩侧索硬化症（Amyotrophic Lateral Sclerosis, ALS）细胞模型中蛋白质的过度聚集。

LU-002i为亚基选择性蛋白酶β2c及β2i抑制剂，其对β2i的IC50为220nM。

PK44 phosphate 是二肽基肽酶 IV (DPP-IV) 的有效抑制剂 (IC50: 15.8 nM)。

16-Hydroxycleroda-3,13-dien-15,16-olide, and prodigiosin are presented as candidates for autophagy inducers that can trigger cell death in a supplement or alternative medicine for cancer therapy. 16-Hydroxycleroda-3,13-dien-15,16-olide regulates the expre

Enzyme-IN-1（compound 1）为基于肽的N端亲核试剂（Ntn）水解酶抑制剂，特别针对20S蛋白酶体的糜胰蛋白酶样活性（CT-L）进行抑制，可能展现出抗炎特性。

LXE408 is an orally active, kinetoplastid-selective proteasome inhibitor, exhibiting non-competitive inhibitory effects. It demonstrates an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. Moreover, LXE408 shows limited ability to traverse the blood-brain barrier. Hence, LXE408 holds promise for advancing research in the field of visceral leishmaniasis (VL).

Antibacterial peptide. Stimulates angiogenesis and inhibits inflammatory responses by selectively blocking proteasome degradation of IκBα.

Gemigliptin (LC15-0444) tartrate hydrate 是一种选择性、可逆且竞争性的二肽基肽酶 4 (DPP-4) 抑制剂，其对人重组DPP-4的IC50值为10.3 nM。Gemigliptin tartrate hydrate 具有显著的抗糖基化特性，并可用于研究与晚期糖基化终产物相关的糖尿病并发症。

Fluostatin A是一种最初从链霉菌中分离出的荧光酮类化合物。它对二肽基肽酶3（DPP-3）的选择性抑制作用优于对DPP-1、DPP-2和DPP-4的抑制作用（IC50s分别为0.44, >100, >100, 和 >100 µg/ml）。